Latest news

As World Cancer Day approaches on Sunday, February 4th, Adalvo reaffirms its commitment to making a meaningful impact in the fight against cancer. With a focus on oncology, Adalvo continues...

Adalvo is pleased to announce the successful DCP submission for Brivaracetam Film-Coated Tablets on Day 1 after the expiry of the Data Exclusivity period, developed in collaboration with one of...

Adalvo is pleased to announce the successful DCP submission for Macitentan 10mg film-coated tablets, developed in collaboration with one of our strategic partners. This product is based on the reference brand Opsumit 10mg film-coated...

Adalvo is pleased to announce the successful DCP approval for Vortioxetine Film-Coated Tablets. The product has been developed based on the reference brand Brintellix, which is indicated for treating major depressive episodes and sold...

Adalvo is very proud to announce the successful DCP approval for Pregabalin Prolonged Release Tablets. Pregabalin Prolonged Release Tablets is a backbone medication indicated in the treatment of Neuropathic pain. Having a unique...

Reference is made to the recent notification issued by the European Medicines Agency on Friday, December 15th, recommending the suspension of more than 350generic medicines. The recommendation follows a Good...

Adalvo, in collaboration with Arphio, is proud to introduce Ambrisentan + Tadalafil Film-Coated Tablets (5mg+20mg, 5mg+40mg, 10mg+40mg), an innovative treatment addressing the urgent unmet needs of patients with Pulmonary Arterial Hypertension. In a phase...

Adalvo is pleased to announce that the Pivotal BE Study for Empagliflozin/Metformin Tablets 12.5/1000mg has been successfully completed.  Our product has been developed based on the reference brand Synjardy 12.5mg/1000mg film-coated Tablets, which is indicated for...

We are pleased to announce the successful DCP approval for Apremilast 10mg, 20mg, 30mg film-coated tablets. Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which is indicated in...

Adalvo is pleased to announce that the successful Pivotal BE Study for Cladribine Tablets 10mg has been completed. Committed to innovation and a proactive market strategy, we are working towards becoming among...

Adalvo is pleased to announce that it has entered into a partnership with Juno Pharmaceuticals Canada, to commercialize a number of respiratory and dermatology dossiers. This licensing and supply agreement includes a basket...

Adalvo is pleased to announce the successful DCP submission for Bosutinib 100, 400, 500mg film-coated tablets, indicated for the treatment of Chronic Myelogenous Leukemia. In 2022, this product achieved global sales...

Adalvo are pleased to announce the successful DCP submission for Afatinib 20, 30, 40, 50mg film-coated tablets. Based on the reference brand, GIOTRIF, Afatinib is indicated for the treatment of metastatic non-small cell...

On this World Diabetes Day, Adalvo showcases the strides made in the realm of diabetic care. Rooted in our commitment to patient well-being, Adalvo stands as one of the leading B2B...

We are pleased to announce our successful DCP submission for Riociguat tablets. Based on the reference brand, Adempas, Riociguat is indicated for the treatment of adult patients with WHO Functional Class (FC) II...

Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS).

Adalvo is excited to remind you that CPhI Barcelona 2023 is just one week away! From October 24th to 26th, we will be part of this exceptional pharmaceutical event, and we've got...

Adalvo and Eurolab are pleased to announce the extension of their long-term strategic collaboration, signing a basket deal for three more products to be marketed and distributed in South Africa and as well as certain SSA...

Adalvo is committed to delivering diversified and competitive assets, supporting our partners in every step of their journey. This is what positions Adalvo for success. We are pleased to announce the successful...

Adalvo is pleased to announce that the successful Pivotal BE Study for Bosutinib Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for November 2023. This product is used...

Adalvo is thrilled to be making remarkable strides in the world of diabetic care. With an unwavering commitment to patient well-being, Adalvo proudly stands alone as the sole B2B company...